Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Restoring Sensitivity to Immunotherapy Post Failure to the Pacific Regimen: A Pilot Study of Combined Durvalumab (MEDI 4736) and Grid Therapy for Non-Small Cell Lung Cancer

NCT05443971 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05443971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05443971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Restoring Sensitivity to Immunotherapy Post Failure to the Pacific Regimen: A Pilot Study of Combined Durvalumab (MEDI 4736) and Grid Therapy for Non-Small Cell Lung Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Terminated
Start date
January 8, 2024
Completion date
December 17, 2025
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung non-small cell carcinoma, stage iii lung cancer ajcc v8